Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01210911
Other study ID # AMCmedonc10/003
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 2010
Est. completion date April 2014

Study information

Verified date April 2021
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pancreatic cancer patients have one of the worst prognoses among all cancer types with a 5 year survival rate of less than 5%. Despite significant changes during the last decade in our molecular knowledge on this disease, the prognosis and management of pancreatic cancer have remained unchanged. With the advances in molecular biology, newer biologic agents such as erlotinib, are adding some benefit to the conventional cytotoxic agents. There is a growing body of literature suggesting that type 2 diabetes mellitus (DM) may be associated with the development of pancreatic cancer, but this association is complex. Because various DM medications can affect directly the key factors mediating the association between DM and pancreatic cancer, understanding the effect of anti-diabetic therapies on pancreatic cancer is a critical step in fully characterizing the role of type 2 DM in the development of pancreatic cancer. Indeed, two epidemiologic studies have found that diabetic patients treated with metformin were less likely to develop cancer, but those treated with insulin were more likely to die of various kinds cancer. Not only does metformin ameliorate hyperglycemia and hyperinsulinemia, both of which are associated with the adverse impact of DM on cancer, metformin also has direct metabolic effects through activation of adenosine monophosphate-activated protein kinase (AMPK). AMPK regulates many metabolic enzymes and also inhibits the mammalian target of rapamycin (mTOR) pathway via phosphorylation and stabilization of the tumor suppressor gene TSC2. But there is an intensive cross-talk between various pathways. Inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway, of which mTOR is one of the effector proteins, for instance may result in escape via the mitogen-activated protein kinase (MAPK) pathway and vice verse. Indeed, epidermal growth factor receptor (EGFR) activation leads to activation of the MAPK pathway and the PI3K pathway. Thus, since it is clear that blocking one pathway will not always be sufficient to produce a response in the presence of other activated pathways, the best change of success will be realized when using a combination of agents that inhibit separate pathways known to be critical to the survival of the tumour. In line with these observations, combining a small molecule against the EGFR and inhibition of the PI3K pathway by metformin might account for potential candidates of the above combinatorial approach. Therefore, in this study, the investigators want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinib and metformin, combined with gemcitabine in patients with metastatic pancreatic cancer.


Description:

In this phase II randomized, placebo controlled study, patients with locally advanced or metastatic pancreatic cancer will be randomized to treatment with gemcitabine, erlotinib and metformin, or gemcitabine, erlotinib and placebo. Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without treatment. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin/ placebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 2014
Est. primary completion date February 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Signed informed content obtained prior to treatment - Cytological or histological confirmed carcinoma of the pancreas - Metastatic cancer - Measurable lesion according to RECIST criteria - ECOG/ WHO performance 0-2 - Age > 18 years - Adequate renal function (creatinine < 150 µmol/L and/ or a creatinine clearance > 60 ml/ L) - Adequate liver function (bilirubin < 1.5 times upper limit of normal, ALAT or ASAT < 5.0 times upper limit of normal in case of liver metastases and < 2.5 the upper limit of normal in absence of liver metastases). - Adequate bone marrow function (WBC > 3.0 x 10 9/L, platelets > 100 x 10 9/L) - Mentally, physically, and geographically able to undergo treatment and follow up Exclusion Criteria: - Clinical or radiological evidence of CNS metastases - Pregnancy (positive serum pregnancy test) and lactation - Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator - Patients who have any severe and/or uncontrolled medical conditions: - unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months prior to randomization, serious uncontrolled cardiac arrhythmia - uncontrolled diabetes as defined by fasting serum glucose >2X ULN. - active or uncontrolled severe infection. - cirrhosis, chronic active hepatitis or chronic persistent hepatitis - severely impaired lung function - Previous treatment with erlotinib - Previous treatment with gemcitabine for metastatic disease - Previous treatment with gemcitabine combined with radiotherapy for locally advanced pancreatic cancer within 6 months prior to study entry - Patients with a known hypersensitivity to metformin - Use of metformin in the previous 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
gemcitabine
Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
erlotinib
Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
metformin
Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
placebo
Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.

Locations

Country Name City State
Netherlands Academic Medical Center Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival after 6 months 6 months after completion of the study
Secondary Progression free survival 6 months after the completion of the study
Secondary Objective response rate expected treatment duration 2- 6 months
Secondary toxicity profile during study and 4 weeks after stop study medication
See also
  Status Clinical Trial Phase
Recruiting NCT04753879 - Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Phase 2
Completed NCT01417000 - Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Phase 2
Active, not recruiting NCT02975141 - Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer Phase 1
Active, not recruiting NCT00761345 - Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer Phase 1
Completed NCT00919282 - Gemcitabine (GFF) in Patients With Pancreatic Cancer Phase 2
Completed NCT01088815 - Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Phase 2
Completed NCT04133155 - Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Withdrawn NCT05251038 - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Phase 1/Phase 2
Recruiting NCT04612530 - PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer Phase 1
Completed NCT03602885 - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options N/A
Recruiting NCT05442749 - Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Recruiting NCT03721744 - A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer Phase 2/Phase 3
Completed NCT03261947 - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Phase 2
Withdrawn NCT06017323 - Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma Phase 1
Terminated NCT01946646 - Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer Phase 1
Completed NCT01523457 - Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Terminated NCT00726037 - A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2